BioCentury | Nov 16, 2018
Financial News

CStone lines up for Hong Kong IPO

...I testing in Australia to treat solid tumors: CS1002, a human mAb against CTLA-4; and CS1003...
BioCentury | Nov 12, 2018
Financial News

CStone lines up for Hong Kong IPO

...I testing in Australia to treat solid tumors: CS1002, a human mAb against CTLA-4; and CS1003...
...HKSE launched its prerevenue biotech chapter in April (see “Hong Kong’s First Wave” ). Alicia Parker CS1001, wbp3155 CS1002 CS1003 CStone...
Items per page:
1 - 2 of 2